Noemi Eiro1, Jesus Fernandez-Gomez2, Raquel Sacristán3, Belen Fernandez-Garcia1, Beatriz Lobo2, Jorge Gonzalez-Suarez2, Alejandro Quintas2, Safwan Escaf1, Francisco J Vizoso4. 1. Unidad de Investigación, Fundación Hospital de Jove, Avda. Eduardo Castro, 161, 33920, Gijón, Asturias, Spain. 2. Unidad de Urología, Hospital Central de Asturias, Universidad de Oviedo, Oviedo, Asturias, Spain. 3. Servicio de Urología, Fundación Hospital de Jove, Avda. Eduardo de Castro, 161, 33920, Gijón, Asturias, Spain. 4. Unidad de Investigación, Fundación Hospital de Jove, Avda. Eduardo Castro, 161, 33920, Gijón, Asturias, Spain. investigacion@hospitaldejove.com.
Abstract
PURPOSE: To detect new predictive markers from the prostate cancer tissue, to study the expression by cultured cancer-associated fibroblasts (CAFs) of stromal factors implicated in prostate carcinogenesis, and to compare their expressions in localized, metastatic, castration-sensitive (CSCP), castration-resistant prostate tumors (CRCP) as well as in fibroblasts from benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: The genomic expression of 20 stroma-derived factors, including the androgen receptor (AR), growth factors (FGF2, FGF7, FGF10, HGF, TGFβ, PDGFB), protein implicated in invasion (MMP-2, MMP-9 and MMP-11), inflammation (IL-6, IL-17, STAT-3 and NFκB), stroma/epithelium interaction (CDH11, FAP, CXCL12 and CXCL14) and chaperones (HPA1A and HSF1), was evaluated in cultured fibroblasts both from BHP and prostate carcinomas (PCa). After isolation and culture of fibroblasts by biopsy specimens, RNA was isolated and genomic studies performed. RESULTS: Finally, 5 BPH and 37 PCa specimens were selected: clinically localized (19), metastatic (5), CSCP (7) and CRPC (6). Interleukin-17 receptor (IL-17RB) was highly expressed in CAFs compared with fibroblasts from BPH. However, metalloproteinase-2 and chemokine ligand 14 (CXCL14) were expressed at higher levels by fibroblasts from BPH. The fibroblastic growth factor-7 was highly expressed by CAFs from localized tumors, but metalloproteinase-11 in metastatic tumors. MMP-11, androgen receptor (AR) and heat-shock-70kda-protein-1A (HSPA1A) expressions were significantly higher in CAFs from CRPC. CONCLUSIONS: These results demonstrate a CAFs heterogeneity among prostate carcinomas with regard to some molecular profile expressions that may be relevant in tumor development (IL-17RB), progression (MMP-11) and castration resistance (AR, MMP-11 and HSPA1A).
PURPOSE: To detect new predictive markers from the prostate cancer tissue, to study the expression by cultured cancer-associated fibroblasts (CAFs) of stromal factors implicated in prostate carcinogenesis, and to compare their expressions in localized, metastatic, castration-sensitive (CSCP), castration-resistant prostate tumors (CRCP) as well as in fibroblasts from benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: The genomic expression of 20 stroma-derived factors, including the androgen receptor (AR), growth factors (FGF2, FGF7, FGF10, HGF, TGFβ, PDGFB), protein implicated in invasion (MMP-2, MMP-9 and MMP-11), inflammation (IL-6, IL-17, STAT-3 and NFκB), stroma/epithelium interaction (CDH11, FAP, CXCL12 and CXCL14) and chaperones (HPA1A and HSF1), was evaluated in cultured fibroblasts both from BHP and prostate carcinomas (PCa). After isolation and culture of fibroblasts by biopsy specimens, RNA was isolated and genomic studies performed. RESULTS: Finally, 5 BPH and 37 PCa specimens were selected: clinically localized (19), metastatic (5), CSCP (7) and CRPC (6). Interleukin-17 receptor (IL-17RB) was highly expressed in CAFs compared with fibroblasts from BPH. However, metalloproteinase-2 and chemokine ligand 14 (CXCL14) were expressed at higher levels by fibroblasts from BPH. The fibroblastic growth factor-7 was highly expressed by CAFs from localized tumors, but metalloproteinase-11 in metastatic tumors. MMP-11, androgen receptor (AR) and heat-shock-70kda-protein-1A (HSPA1A) expressions were significantly higher in CAFs from CRPC. CONCLUSIONS: These results demonstrate a CAFs heterogeneity among prostate carcinomas with regard to some molecular profile expressions that may be relevant in tumor development (IL-17RB), progression (MMP-11) and castration resistance (AR, MMP-11 and HSPA1A).
Authors: Noemí Eiró; Belen Fernandez-Garcia; Julio Vázquez; José M Del Casar; Luis O González; Francisco J Vizoso Journal: Oncoimmunology Date: 2015-01-29 Impact factor: 8.110
Authors: Michael Quante; Shui Ping Tu; Hiroyuki Tomita; Tamas Gonda; Sophie S W Wang; Shigeo Takashi; Gwang Ho Baik; Wataru Shibata; Bethany Diprete; Kelly S Betz; Richard Friedman; Andrea Varro; Benjamin Tycko; Timothy C Wang Journal: Cancer Cell Date: 2011-02-15 Impact factor: 31.743
Authors: Kazutoshi Fujita; Charles M Ewing; Lori J Sokoll; Debra J Elliott; Mark Cunningham; Angelo M De Marzo; William B Isaacs; Christian P Pavlovich Journal: Prostate Date: 2008-06-01 Impact factor: 4.104
Authors: Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso Journal: Pathol Oncol Res Date: 2019-02-01 Impact factor: 3.201
Authors: Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon Journal: Mol Carcinog Date: 2020-03-24 Impact factor: 4.784
Authors: Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo Journal: Int J Mol Sci Date: 2017-07-21 Impact factor: 5.923
Authors: Kerstin Junker; Matthias Saar; Johannes Linxweiler; Turkan Hajili; Christina Körbel; Carolina Berchem; Philip Zeuschner; Andreas Müller; Michael Stöckle; Michael D Menger Journal: Sci Rep Date: 2020-07-28 Impact factor: 4.379